IC
CCXI

Ikarian Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

Ikarian Capital’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-600,000
Closed -$10.3M – 244
2021
Q3 		$10.3M Buy
600,000
+378,800
+171% +$5.9M 0.72% 38
2021
Q2 		$2.96M Buy
221,200
+21,200
+11% +$522K 0.24% 98
2021
Q1 		$10.2M Buy
+200,000
New +$12M 0.34% 67
2020
Q4 		– Sell
-100,000
Closed -$5.48M – 262
2020
Q3 		$5.48M Buy
+100,000
New +$5.38M 0.4% 65
2020
Q2 		– Sell
-150,000
Closed -$6.03M – 214
2020
Q1 		$6.03M Buy
+150,000
New +$6.37M 0.45% 54

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ikarian Capital's CCXI Position: Q3 2021 in Review

Ikarian Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2021, closing a stake of 471,376 shares — an estimated $7.34M sold.

Ikarian Capital first reported a position in CCXI in Q4 2019 and held it in 4 quarters. The position peaked at $6.31M in Q2 2021. 140 funds tracked by Wall St. Rank hold CCXI as of Q3 2021.

  • Ikarian Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 471,376 ChemoCentryx, Inc. shares in Q3 2021, an estimated $7.34M.
  • Ikarian Capital first reported a position in ChemoCentryx, Inc. in Q4 2019 and held it in 4 quarters.
  • Ikarian Capital's ChemoCentryx, Inc. position peaked at $6.31M in Q2 2021.
  • 140 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.